APA (7th ed.) Citation

L, E., E, R., S, M., PK, T., MS, C., K, S., & J, K. (2024). Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. Clinical breast cancer, 24(8), 676. https://doi.org/10.1016/j.clbc.2024.07.002

Chicago Style (17th ed.) Citation

L, Elsayed, Reed E, Modi S, Tandra PK, Copur MS, Samson K, and Krishnamurthy J. "Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer." Clinical Breast Cancer 24, no. 8 (2024): 676. https://doi.org/10.1016/j.clbc.2024.07.002.

MLA (9th ed.) Citation

L, Elsayed, et al. "Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer." Clinical Breast Cancer, vol. 24, no. 8, 2024, p. 676, https://doi.org/10.1016/j.clbc.2024.07.002.